Cochlear Not Yet a Pick Despite Shaking Bear -- Market Talk

Dow Jones11-01

0317 GMT - Cochlear shakes off its bear at Macquarie but remains less attractive to the investment bank's analysts than other Australia-listed medical-technology stocks. Shares in the hearing-implant manufacturer have fallen by about 16% since August. This leaves the stock at a level implying market-share gains and profit margins in line with Macquarie analysts' expectations. However, they point out that it is trading at about 42 times EPS on a 12-month forward basis, compared with about 27 for vaccine maker CSL and 25 for breath-tech provider ResMed. Both those companies are forecast to grow fiscal 2025 EPS at a faster rate, they add. Macquarie raises its target price by 2.1% to A$289.00 and upgrades its recommendation to neutral from underperform. Shares are up 0.35% at A$284.24. (stuart.condie@wsj.com)

(END) Dow Jones Newswires

October 31, 2024 23:17 ET (03:17 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2480043073?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-01 11:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2480043073","market":"other","top_or_hot":-1,"title":"Cochlear Not Yet a Pick Despite Shaking Bear -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0317 GMT - Cochlear shakes off its bear at <a href=\"https://laohu8.com/S/MQG.AU\">Macquarie</a> but remains less attractive to the investment bank's analysts than other Australia-listed medical-technology stocks. Shares in the hearing-implant manufacturer have fallen by about 16% since August. This leaves the stock at a level implying market-share gains and profit margins in line with Macquarie analysts' expectations. However, they point out that it is trading at about 42 times EPS on a 12-month forward basis, compared with about 27 for vaccine maker CSL and 25 for breath-tech provider ResMed. Both those companies are forecast to grow fiscal 2025 EPS at a faster rate, they add. Macquarie raises its target price by 2.1% to A$289.00 and upgrades its recommendation to neutral from underperform. Shares are up 0.35% at A$284.24. (stuart.condie@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 31, 2024 23:17 ET (03:17 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cochlear Not Yet a Pick Despite Shaking Bear -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCochlear Not Yet a Pick Despite Shaking Bear -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-01 11:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>0317 GMT - Cochlear shakes off its bear at Macquarie but remains less attractive to the investment bank's analysts than other Australia-listed medical-technology stocks. Shares in the hearing-implant ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7007","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2480043073","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2480043073","pubTimestamp":1730431020,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0317 GMT - Cochlear shakes off its bear at Macquarie but remains less attractive to the investment bank's analysts than other Australia-listed medical-technology stocks. Shares in the hearing-implant manufacturer have fallen by about 16% since August. This leaves the stock at a level implying market-share gains and profit margins in line with Macquarie analysts' expectations. However, they point out that it is trading at about 42 times EPS on a 12-month forward basis, compared with about 27 for vaccine maker CSL and 25 for breath-tech provider ResMed. Both those companies are forecast to grow fiscal 2025 EPS at a faster rate, they add. Macquarie raises its target price by 2.1% to A$289.00 and upgrades its recommendation to neutral from underperform. Shares are up 0.35% at A$284.24. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7007":"医疗保健设备","COH.AU":"COCHLEAR LTD"},"translate_title":"尽管熊市摇摇欲坠，耳蜗尚未成为选择——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"COH.AU":0.9},"content_text":"0317 GMT - Cochlear shakes off its bear at Macquarie but remains less attractive to the investment bank's analysts than other Australia-listed medical-technology stocks. Shares in the hearing-implant manufacturer have fallen by about 16% since August. This leaves the stock at a level implying market-share gains and profit margins in line with Macquarie analysts' expectations. However, they point out that it is trading at about 42 times EPS on a 12-month forward basis, compared with about 27 for vaccine maker CSL and 25 for breath-tech provider ResMed. Both those companies are forecast to grow fiscal 2025 EPS at a faster rate, they add. Macquarie raises its target price by 2.1% to A$289.00 and upgrades its recommendation to neutral from underperform. Shares are up 0.35% at A$284.24. (stuart.condie@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 31, 2024 23:17 ET (03:17 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2480043073"}